Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: A longitudinal study in multiple sclerosis patients

Clinical and Experimental Immunology

Volumn 179, Issue 1, 2015, Pages 119-127

  Sanchez Lopez A J ^a   Roman Vega L ^a   Ramil Tojeiro, E ^a   Giuffrida, A ^b   Garcia Merino A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cannabinoid receptors; Endocannabinoids; Interferon beta; Multiple sclerosis

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; BETA INTERFERON; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; AMIDASE; CANNABINOID 1 RECEPTOR; FATTY-ACID AMIDE HYDROLASE; MESSENGER RNA;

ADULT; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LONGITUDINAL STUDY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; ADOLESCENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AMIDOHYDROLASES; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RNA, MESSENGER; YOUNG ADULT;

EID: 84927694130     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12443     Document Type: Article

References (36)

1. Frischer JM, Bramow S, Dal-Bianco A etal. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132:1175-1189.
2. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51:682-689.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
5. Howlett AC, Barth F, Bonner TI etal. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161-202.
6. Sanchez AJ, Garcia-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol 2012; 142:57-67.
7. Pryce G, Ahmed Z, Hankey DJ etal. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126:2191-2202.
8. Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008; 286:S91-S96.
9. Cencioni MT, Chiurchiu V, Catanzaro G etal. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLOS ONE 2010; 5:e8688.
10. Ihenetu K, Molleman A, Parsons M, Whelan C. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 464:207-215.
11. Malfitano AM, Laezza C, D'Alessandro A etal. Effects on immune cells of a new 1, 8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis. PLOS ONE 2013; 8:e62511.
12. Benito C, Romero JP, Tolon RM etal. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007; 27:2396-2402.
13. Centonze D, Bari M, Rossi S etal. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007; 130:2543-2553.
14. Di FM, Pini LA, Pelliccioli GP, Calabresi P, Sarchielli P. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:1224-1229.
15. Jean-Gilles L, Feng S, Tench CR etal. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009; 287:212-215.
16. Galiegue S, Mary S, Marchand J etal. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232:54-61.
17. Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M. Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 2010; 23:25-34.
18. Polman CH, Reingold SC, Edan G etal. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald criteria'. Ann Neurol 2005; 58:840-846.
19. Hardison S, Weintraub ST, Giuffrida A. Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat 2006; 81:106-112.
20. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 2002; 127:169-176.
21. Izzo AA, Fezza F, Capasso R etal. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134:563-570.
22. Borner C, Hollt V, Sebald W, Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 2007; 81:336-343.
23. Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 2002; 68-69:521-534.
24. Fezza F, De SC, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 2008; 49:101-132.
25. Klein TW, Newton C, Larsen K etal. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74:486-496.
26. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683-747.
27. Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 2010; 215:606-610.
28. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011; 25:491-502.
29. Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011; 7:221-228.
30. Malucchi S, Gilli F, Caldano M etal. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008; 70:1119-1127.
31. Cabranes A, Venderova K, de Lago E etal. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20:207-217.
32. Witting A, Chen L, Cudaback E etal. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci USA 2006; 103:6362-6367.
33. Eljaschewitsch E, Witting A, Mawrin C etal. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006; 49:67-79.
34. Vogeser M, Hauer D, Christina AS, Huber E, Storr M, Schelling G. Release of anandamide from blood cells. Clin Chem Lab Med 2006; 44:488-491.
35. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008; 14:2326-2336.
36. Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 2005; 137:217-223.